Ricerca Indipendente - Psoriasi

E' partita la fase II per un nuovo farmaco topico che agirebbe inibendo contemporaneamente la Dipeptidyl Peptidase IV e la Aminopeptidase N.

Il farmaco, la cui sigla provvisoria è IP10:C8, deriva da un brevetto della tedesca Immune Technologies and Medicine (IMTM) chiamato Peptidase Targeted Immune Regulation (PETIR™)

PETIR™ therapy involves the combined inhibition of two peptidases that are chiefly responsible for immune response (DPIV and APN families), by using dual inhibitors. PETIR™ is realized by the use of single NCEs that combine both inhibitory modes of action into a single substance.

This completely new approach acts both, on central regulatory mechanisms of the immune system, by activation of regulatory T cells and direct inhibition of activation and proliferation of activated immune effector cells. This holds true for TH1 as well as TH2 mediated immune responses.